Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Tradenride who wrote (25462)	2/16/2004 8:30:46 AM
From: Tradenride	Respond to of 25711

EXTI's 10k reveals a more instructive cash flow and now that the reorganization of their Multicell subsidiary is complete we should see a positive 10Q in April. The reorganization was a transition into commercialization of their immortalized human liver cell lines, a 3.7 billion market potential. They have received 1.5mil in cash as part of a 7 year distribution contract that includes royalties with Xenotech and their cell lines have been validated by Pfizer and Roche. EXTI signed a 15-year license agreement with Pfizer for non-exclusive research use of our two proprietary human liver cell lines. IMO Roche is next.